ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-MET / Metabolic and incretin signalling

Retatrutide

Also known as: LY3437943

Human evidence

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

An investigational triple-receptor agonist peptide. Human phase 2 data has been published. It is not a component of any FDA-approved drug.

Evidence position

Grade B. Human interventional evidence exists; no approved comparator. FDA has stated retatrutide cannot be used in compounding under federal law.

What the record does not establish

Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.

Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.

Sources

  • 01
    Phase 2 human trialPubMed
    Shows
    Human interventional data for the investigational molecule
    Does not show
    Investigational; no approved comparator
  • 02
    FDA concerns with unapproved GLP-1 drugsU.S. Food and Drug Administration
    Shows
    Explicit regulator position on this molecule
    Does not show
    Not a quality assessment of any vial

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine / 2023 Aug 10PMID 37366315 / DOI 10.1056/NEJMoa2301972
  2. Retatrutide-A Game Changer in Obesity Pharmacotherapy.Biomolecules / 2025 May 30PMID 40563436 / DOI 10.3390/biom15060796
  3. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes care / 2024 Nov 1PMID 38843460 / DOI 10.2337/dci24-0003
  4. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.Diabetes, obesity & metabolism / 2026 JanPMID 41090431 / DOI 10.1111/dom.70209
  5. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?Diabetes care / 2024 Oct 1PMID 38687506 / DOI 10.2337/dci23-0100

CLINICALTRIALS.GOV / FOUND RECORDS

  1. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightCOMPLETED / PHASE3 / Eli Lilly and CompanyNCT05929079 / DIRECT intervention MATCH: Retatrutide
  2. Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightRECRUITING / PHASE2 / Hudson BiotechNCT07467447 / DIRECT intervention MATCH: Retatrutide
  3. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ACTIVE_NOT_RECRUITING / PHASE3 / Eli Lilly and CompanyNCT06383390 / DIRECT intervention MATCH: Retatrutide
  4. Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)ACTIVE_NOT_RECRUITING / PHASE3 / Eli Lilly and CompanyNCT06260722 / DIRECT intervention MATCH: Retatrutide
  5. A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusACTIVE_NOT_RECRUITING / PHASE1 / Eli Lilly and CompanyNCT06982859 / DIRECT intervention MATCH: Retatrutide

Related compounds

RM-MET

Tirzepatide

Read entry →
RM-MET

Cagrilintide

Read entry →